H.R. 1266 Passed the House Crime and Law Enforcement

Combating Illicit Xylazine Act

To prohibit certain uses of xylazine, and for other purposes.

  1. Introduced
  2. Committee
  3. Passed House
  4. Passed Senate
  5. To President
  6. Became law
Sponsor Rep. Panetta, Jimmy [D-CA-19] Introduced February 12, 2025 Cosponsors 114 (63 R, 51 D) Latest action September 16, 2026

Summary

Combating Illicit Xylazine Act
This bill regulates xylazine under the Controlled Substances Act (CSA).
Xylazine, also known as tranq, is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine.
This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused.
Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA.
The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs.
The bill also exempts xylazine manufacturers from the CSA's physical security requirements.
Finally, the bill requires the DEA, in coordination with the Food and Drug Administration, to report on (1) the prevalence and impact of illicit xylazine use in the United States, and (2) updated information on the prevalence and proliferation of xylazine trafficking and misuse in the United States.

Summary by the Congressional Research Service, Library of Congress.

Congress.gov

Actions

  1. Sep 16, 2026 Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.
  2. Sep 15, 2026 Motion to reconsider laid on the table Agreed to without objection.
  3. Sep 15, 2026 On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5671-5672)
  4. Sep 15, 2026 Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  5. Sep 15, 2026 DEBATE - The House proceeded with forty minutes of debate on H.R. 1266.
  6. Sep 15, 2026 Considered under suspension of the rules. (consideration: CR H5671-5673)
  7. Sep 15, 2026 Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
  8. Sep 14, 2026 Placed on the Union Calendar, Calendar No. 715.
  9. Sep 14, 2026 Committee on the Judiciary discharged.
  10. Sep 14, 2026 Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-816, Part I.
  11. Jul 21, 2026 Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 48 - 0.
  12. Jul 21, 2026 Committee Consideration and Mark-up Session Held

Congressional and federal records come from official public sources: the House Clerk, the U.S. Senate, GovInfo and the Library of Congress (bill status), the Federal Register, and the congress-legislators project. They are copied on a schedule and may lag the official record by a few hours; the official sources govern. News and coverage counts are drawn from the 4Search index and reflect what the press published, not 4Search's views. Nothing here is an endorsement of any candidate, party or position. Terms of use.